NCT06085833
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Recruiting · Not Applicable · ARTIDIS AG · registry updated 2026-09-22
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.
Inclusion
- Patients aged ≥ 18 years
- Ability to understand and the willingness to sign a written informed consent.
- Indication for breast biopsy for diagnostic purposes
- ECOG performance status of 0 to 3.
Exclusion
- Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.